← Back to Search

Local Anesthetic

Liposomal Bupivacaine for Colorectal Surgery

Phase 3
Waitlist Available
Led By Yar Yeap, MD
Research Sponsored by Indiana University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up time from end of surgery to time of os (usually 4-16 hours)
Awards & highlights

Study Summary

The purpose of this study is to compare the difference between two different pain control methods in patients who will be having a colorectal surgery

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~time from end of surgery to time of os (usually 4-16 hours)
This trial's timeline: 3 weeks for screening, Varies for treatment, and time from end of surgery to time of os (usually 4-16 hours) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
VAS Score at 1 Hour With Movement
VAS Score at 1 Hour at Rest
VAS Score at 24 Hours With Movement
+5 more
Secondary outcome measures
Total Opioid Consumption at 1 Hour
Total Opioid Consumption at 24 Hour
Total Opioid Consumption at 48 Hour
+1 more
Other outcome measures
Ambulatory Postoperatively
Length of Stay
Nausea Scores (Mild) at 1 Hour
+26 more

Trial Design

2Treatment groups
Active Control
Group I: Liposomal BupivacaineActive Control1 Intervention
LB (Liposomal Bupivacaine) group - This group will be receiving 20 mL EXPAREL (266mg) and 40 mL of 0.125% bupivacaine in total, 30ml on each side. For the QL block, Shamrock sign consistent of the quadratus lumborum muscle, psoas major muscle, erector spinae muscles and the L4 transverse process will be identified. Under ultrasound guidance with an in-plane technique, the needle will be advanced into the fascial plane between the quadratus lumborum and psoas major muscles. Local anesthetic will be injected into the plane.
Group II: Standard BupivacaineActive Control1 Intervention
SB (Standard Bupivacaine) group - This group will be receiving 60 mL of 0.25% bupivacaine in total, 30 mL on each side. For the QL block, Shamrock sign consistent of the quadratus lumborum muscle, psoas major muscle, erector spinae muscles and the L4 transverse process will be identified. Under ultrasound guidance with an in-plane technique, the needle will be advanced into the fascial plane between the quadratus lumborum and psoas major muscles. Local anesthetic will be injected into the plane.

Find a Location

Who is running the clinical trial?

Indiana UniversityLead Sponsor
980 Previous Clinical Trials
983,213 Total Patients Enrolled
Yar Yeap, MDPrincipal InvestigatorIndiana University
6 Previous Clinical Trials
600 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Comparing Liposomal Bupivacaine Versus Standard Bupivacaine in Colorectal Surgery
Yar Yeap 2018. "Comparing Liposomal Bupivacaine Versus Standard Bupivacaine in Colorectal Surgery". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03702621.
~14 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top